
Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain
Contineum Therapeutics Announces Encouraging Topline Results from Exploratory Phase 1b Study of PIPE-791 in Chronic Pain Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on advancing differentiated therapies…












